INFANTILE IDIOPATHIC MYOPATHIC CARNITINE DEFICIENCY - TREATMENT WITH L-CARNITINE

被引:15
|
作者
SHAPIRA, Y
GLICK, B
HAREL, S
VATTIN, JJ
GUTMAN, A
机构
[1] TEL AVIV UNIV,DIV CHILD NEUROL,IL-69978 TEL AVIV,ISRAEL
[2] MED CTR,TEL AVIV,ISRAEL
关键词
D O I
10.1016/0887-8994(93)90007-Y
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A series of 9 infants, ranging in age from 3 months to 5 years (average: 2 years), suffered from idiopathic myopathic carnitine deficiency presenting as hypotonia and motor delay. Secondary carnitine deficiency was eliminated by appropriate tests. Muscle carnitine concentration ranged from 2.3-7.1 nmol/mg non-collagen protein (NCP; average: 4.87 nmol/mg NCP; normal: 22 +/- 6 nmol/mg NCP). Lipid accumulation in muscle was observed in 2 of 8 patients. Therapy with L-carnitine (100 mg/kg/day in most patients) was given with clinical and laboratory follow-up 6 months later. In 7 of 9 patients, muscle tone and motor function improved. Muscle carnitine concentration increased to a range of 2.7-23.4 nmol/mg (average: 12.27 nmol/mg). In some patients the muscle carnitine content multiplied by a factor of 3-4, but carnitine concentration reached the normal range in only 2 patients. Most infants with idiopathic carnitine deficiency did benefit from 6 months of therapy; however, in order to achieve full recovery the duration of therapy should probably continue for longer periods, with a dose of not less than 100 mg/kg/day.
引用
收藏
页码:35 / 38
页数:4
相关论文
共 50 条
  • [41] Pharmacokinetics of L-carnitine
    Evans, AM
    Fornasini, G
    [J]. CLINICAL PHARMACOKINETICS, 2003, 42 (11) : 941 - 967
  • [42] Conversion of D-carnitine into L-carnitine with stereospecific carnitine dehydrogenases
    Hanschmann, H
    Kleber, HP
    [J]. BIOTECHNOLOGY LETTERS, 1997, 19 (07) : 679 - 682
  • [43] L-CARNITINE FOR METHYLMALONICACIDURIA
    SECCOMBE, DW
    SNYDER, F
    PARSONS, HG
    [J]. LANCET, 1982, 2 (8312): : 1401 - 1401
  • [44] USE OF D,L-CARNITINE AND L-CARNITINE IN UREMIC PATIENTS ON INTERMITTENT HEMODIALYSIS
    MIOLI, V
    TARCHINI, R
    BOGGI, R
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 1982, 2 (02) : 143 - 148
  • [45] L-CARNITINE DEFICIENCY IN BETA-THALASSEMIA MAJOR
    Ucar, Kalkan S.
    Karapinar, Yilmaz D.
    Balkan, C.
    Kavakli, K.
    Bozdemir, E.
    Parildar, Z.
    Habif, S.
    Bayindir, O.
    Coker, M.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2012, 35 : S170 - S170
  • [46] L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblasts
    Mori, G
    Colucci, S
    Greco, G
    Vaira, S
    Simone, GM
    Mancini, L
    Sardelli, F
    Koverech, A
    Zambonin-Zallone, A
    Grano, M
    [J]. BONE, 2002, 30 (03) : 9S - 9S
  • [47] L-CARNITINE DEFICIENCY IN THE SYRIAN-HAMSTER AND RAT
    PAULSON, DJ
    TRIPP, ME
    LEMANSKI, LF
    SHUG, AL
    [J]. FEDERATION PROCEEDINGS, 1981, 40 (06) : 1589 - 1589
  • [48] Conversion of D-carnitine into L-carnitine with stereospecific carnitine dehydrogenases
    Henning Hanschmann
    Hans-Peter Kleber
    [J]. Biotechnology Letters, 1997, 19 : 679 - 682
  • [49] L-carnitine and erytropoietin treatment in hemodialysis patients
    Dejanova, B.
    Dejanov, P.
    Sikole, A.
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2007, 30 (08): : 742 - 742
  • [50] AN INVESTIGATION OF L-CARNITINE TREATMENT IN THE HYPERLIPIDEMIC RABBIT
    SECCOMBE, DW
    JAMES, L
    JONES, E
    HAHN, P
    [J]. FEDERATION PROCEEDINGS, 1987, 46 (04) : 1340 - 1340